| Literature DB >> 30671125 |
Guoming Chen1, Chuyao Huang1, Yunyun Liu1, Tengyu Chen1, Ruilan Huang1, Miaozhen Liang1, Jie Zhang1, Hua Xu2.
Abstract
OBJECTIVE: To predict and explore the potential mechanism of Yinchensini decoction (YCSND) based on systemic pharmacology.Entities:
Year: 2018 PMID: 30671125 PMCID: PMC6317126 DOI: 10.1155/2018/2178610
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Information for 126 chemical ingredients of YCSD.
|
|
|
|
|
|
|---|---|---|---|---|
| MOL004609 | Areapillin | 48.96 | 0.41 | Yinchen |
| MOL005573 | Genkwanin | 37.13 | 0.24 | |
| MOL007274 | Skrofulein | 30.35 | 0.3 | |
| MOL008039 | Isoarcapillin | 57.4 | 0.41 | |
| MOL008040 | Eupalitin | 46.11 | 0.33 | |
| MOL008041 | Eupatolitin | 42.55 | 0.37 | |
| MOL008043 | Capillarisin | 57.56 | 0.31 | |
| MOL008045 | 4'-Methylcapillarisin | 72.18 | 0.35 | |
| MOL008046 | Demethoxycapillarisin | 52.33 | 0.25 | |
| MOL008047 | Artepillin A | 68.32 | 0.24 | |
| MOL002211 | 11,14-eicosadienoic acid | 39.99 | 0.2 | Fuzi |
| MOL002388 | Delphin_qt | 57.76 | 0.28 | |
| MOL002392 | Deltoin | 46.69 | 0.37 | |
| MOL002393 | Demethyldelavaine A | 34.52 | 0.18 | |
| MOL002394 | Demethyldelavaine B | 34.52 | 0.18 | |
| MOL002395 | Deoxyandrographolide | 56.3 | 0.31 | |
| MOL002397 | Karakoline | 51.73 | 0.73 | |
| MOL002398 | Karanjin | 69.56 | 0.34 | |
| MOL002401 | Neokadsuranic acid B | 43.1 | 0.85 | |
| MOL002406 | 2,7-Dideacetyl-2,7-dibenzoyl-taxayunnanine F | 39.43 | 0.38 | |
| MOL002410 | Benzoylnapelline | 34.06 | 0.53 | |
| MOL002415 | 6-Demethyldesoline | 51.87 | 0.66 | |
| MOL002416 | deoxyaconitine | 30.96 | 0.24 | |
| MOL002419 | (R)-Norcoclaurine | 82.54 | 0.21 | |
| MOL002421 | Ignavine | 84.08 | 0.25 | |
| MOL002422 | Isotalatizidine | 50.82 | 0.73 | |
| MOL002423 | Jesaconitine | 33.41 | 0.19 | |
| MOL002433 | (3R,8S,9R,10R,13R,14S,17R)-3-hydroxy-4,4,9,13,14-pentamethyl-17-[(E,2R)-6-methyl-7-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-1,2,3,7,8,10,12,15,16,17-decahydr | 41.52 | 0.22 | |
| MOL002434 | Carnosifloside I_qt | 38.16 | 0.8 | |
| MOL000538 | Hypaconitine | 31.39 | 0.26 | |
| MOL002464 | 1-Monolinolein | 37.18 | 0.3 | |
| MOL002501 | [(1S)-3-[(E)-but-2-enyl]-2-methyl-4-oxo-1-cyclopent-2-enyl] (1R,3R)-3-[(E)-3-methoxy-2-methyl-3-oxoprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate | 62.52 | 0.31 | Ganjiang |
| MOL002514 | Sexangularetin | 62.86 | 0.3 | |
| MOL004898 | (E)-3-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-1-(2,4-dihydroxyphenyl)prop-2-en-1-one | 46.27 | 0.31 | |
| MOL004903 | Liquiritin | 65.69 | 0.74 | |
| MOL004904 | Licopyranocoumarin | 80.36 | 0.65 | |
| MOL004905 | 3,22-Dihydroxy-11-oxo-delta(12)-oleanene-27-alpha-methoxycarbonyl-29-oic acid | 34.32 | 0.55 | |
| MOL004907 | Glyzaglabrin | 61.07 | 0.35 | |
| MOL004908 | Glabridin | 53.25 | 0.47 | |
| MOL004910 | Glabranin | 52.9 | 0.31 | |
| MOL004911 | Glabrene | 46.27 | 0.44 | |
| MOL004912 | Glabrone | 52.51 | 0.5 | |
| MOL004913 | 1,3-dihydroxy-9-methoxy-6-benzofurano[3,2-c]chromenone | 48.14 | 0.43 | |
| MOL004914 | 1,3-dihydroxy-8,9-dimethoxy-6-benzofurano[3,2-c]chromenone | 62.9 | 0.53 | |
| MOL004915 | Eurycarpin A | 43.28 | 0.37 | |
| MOL004917 | Glycyroside | 37.25 | 0.79 | |
| MOL004924 | (-)-Medicocarpin | 40.99 | 0.95 | Gancao |
| MOL004935 | Sigmoidin-B | 34.88 | 0.41 | |
| MOL004941 | (2R)-7-hydroxy-2-(4-hydroxyphenyl)chroman-4-one | 71.12 | 0.18 | |
| MOL004945 | (2S)-7-hydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)chroman-4-one | 36.57 | 0.32 | |
| MOL004948 | Isoglycyrol | 44.7 | 0.84 | |
| MOL004949 | Isolicoflavonol | 45.17 | 0.42 | |
| MOL004957 | HMO | 38.37 | 0.21 | |
| MOL004959 | 1-Methoxyphaseollidin | 69.98 | 0.64 | |
| MOL004961 | Quercetin der. | 46.45 | 0.33 | |
| MOL004966 | 3'-Hydroxy-4'-O-Methylglabridin | 43.71 | 0.57 | |
| MOL000497 | licochalcone a | 40.79 | 0.29 | |
| MOL004974 | 3'-Methoxyglabridin | 46.16 | 0.57 | |
| MOL004978 | 2-[(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano[6,5-f]chromen-3-yl]-5-methoxyphenol | 36.21 | 0.52 | |
| MOL004980 | Inflacoumarin A | 39.71 | 0.33 | |
| MOL004985 | icos-5-enoic acid | 30.7 | 0.2 | |
| MOL004988 | Kanzonol F | 32.47 | 0.89 | |
| MOL004989 | 6-prenylated eriodictyol | 39.22 | 0.41 | |
| MOL004990 | 7,2',4'-trihydroxy—5-methoxy-3—arylcoumarin | 83.71 | 0.27 | |
| MOL004991 | 7-Acetoxy-2-methylisoflavone | 38.92 | 0.26 | |
| MOL004993 | 8-prenylated eriodictyol | 53.79 | 0.4 | |
| MOL004996 | gadelaidic acid | 30.7 | 0.2 | |
| MOL000500 | Vestitol | 74.66 | 0.21 | |
| MOL005000 | Gancaonin G | 60.44 | 0.39 | |
| MOL005001 | Gancaonin H | 50.1 | 0.78 | |
| MOL005003 | Licoagrocarpin | 58.81 | 0.58 | |
| MOL005007 | Glyasperins M | 72.67 | 0.59 | |
| MOL005008 | Glycyrrhiza flavonol A | 41.28 | 0.6 | |
| MOL005012 | Licoagroisoflavone | 57.28 | 0.49 | |
| MOL005013 | 18 | 41.16 | 0.71 | |
| MOL005016 | Odoratin | 49.95 | 0.3 | |
| MOL005017 | Phaseol | 78.77 | 0.58 | |
| MOL005018 | Xambioona | 54.85 | 0.87 | |
| MOL001484 | Inermine | 75.18 | 0.54 | |
| MOL001792 | DFV | 32.76 | 0.18 | |
| MOL000211 | Mairin | 55.38 | 0.78 | |
| MOL002311 | Glycyrol | 90.78 | 0.67 | |
| MOL000239 | Jaranol | 50.83 | 0.29 | |
| MOL002565 | Medicarpin | 49.22 | 0.34 | |
| MOL003656 | Lupiwighteone | 51.64 | 0.37 | |
| MOL003896 | 7-Methoxy-2-methyl isoflavone | 42.56 | 0.2 | |
| MOL000392 | Formononetin | 69.67 | 0.21 | |
| MOL000417 | Calycosin | 47.75 | 0.24 | |
| MOL000422 | Kaempferol | 41.88 | 0.24 | |
| MOL004328 | Naringenin | 59.29 | 0.21 | |
| MOL004805 | (2S)-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-8,8-dimethyl-2,3-dihydropyrano[2,3-f]chromen-4-one | 31.79 | 0.72 | |
| MOL004806 | euchrenone | 30.29 | 0.57 | |
| MOL004808 | Glyasperin B | 65.22 | 0.44 | |
| MOL004810 | Glyasperin F | 75.84 | 0.54 | |
| MOL004811 | Glyasperin C | 45.56 | 0.4 | |
| MOL004814 | Isotrifoliol | 31.94 | 0.42 | |
| MOL004815 | (E)-1-(2,4-dihydroxyphenyl)-3-(2,2-dimethylchromen-6-yl)prop-2-en-1-one | 39.62 | 0.35 | |
| MOL004820 | Kanzonol W | 50.48 | 0.52 | |
| MOL004824 | (2S)-6-(2,4-dihydroxyphenyl)-2-(2-hydroxypropan-2-yl)-4-methoxy-2,3-dihydrofuro[3,2-g]chromen-7-one | 60.25 | 0.63 | |
| MOL004827 | Semilicoisoflavone B | 48.78 | 0.55 | |
| MOL004828 | Glepidotin A | 44.72 | 0.35 | |
| MOL004829 | Glepidotin B | 64.46 | 0.34 | |
| MOL004833 | Phaseolinisoflavan | 32.01 | 0.45 | |
| MOL004835 | Glypallichalcone | 61.6 | 0.19 | |
| MOL004838 | 8-(6-hydroxy-2-benzofuranyl)-2,2-dimethyl-5-chromenol | 58.44 | 0.38 | |
| MOL004841 | Licochalcone B | 76.76 | 0.19 | |
| MOL004848 | licochalcone G | 49.25 | 0.32 | |
| MOL004849 | 3-(2,4-dihydroxyphenyl)-8-(1,1-dimethylprop-2-enyl)-7-hydroxy-5-methoxy-coumarin | 59.62 | 0.43 | |
| MOL004855 | Licoricone | 63.58 | 0.47 | |
| MOL004856 | Gancaonin A | 51.08 | 0.4 | |
| MOL004857 | Gancaonin B | 48.79 | 0.45 | |
| MOL004860 | licorice glycoside E | 32.89 | 0.27 | |
| MOL004863 | 3-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-(3-methylbut-2-enyl)chromone | 66.37 | 0.41 | |
| MOL004864 | 5,7-dihydroxy-3-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromone | 30.49 | 0.41 | |
| MOL004866 | 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-(3-methylbut-2-enyl)chromone | 44.15 | 0.41 | |
| MOL004879 | Glycyrin | 52.61 | 0.47 | |
| MOL004882 | Licocoumarone | 33.21 | 0.36 | |
| MOL004883 | Licoisoflavone | 41.61 | 0.42 | |
| MOL004884 | Licoisoflavone B | 38.93 | 0.55 | |
| MOL004885 | Licoisoflavanone | 52.47 | 0.54 | |
| MOL004891 | Shinpterocarpin | 80.3 | 0.73 | |
| MOL005020 | Dehydroglyasperin C | 53.82 | 0.37 | |
| MOL000354 | Isorhamnetin | 49.6 | 0.31 | Yinchen |
| MOL000358 | Beta-sitosterol | 36.91 | 0.75 | Yinchen |
| MOL000098 | Quercetin | 46.43 | 0.28 | Yinchen |
| MOL000359 | Sitosterol | 36.91 | 0.75 | Fuzi |
Figure 1The compound-target network of YCSND.
Important node of YCSND compound-target network.
|
|
|
|
|
|---|---|---|---|
| Quercetin | Compound | 154 | 0.51220399 |
| Prostaglandin G/H synthase 2 | Target | 98 | 0.09990361 |
| Estrogen receptor | Target | 80 | 0.03095638 |
| Calmodulin | Target | 77 | 0.01919701 |
| Heat shock protein HSP 90 | Target | 74 | 0.06433216 |
| Nitric oxide synthase, inducible | Target | 74 | 0.01539794 |
| Androgen receptor | Target | 73 | 0.03326497 |
| Kaempferol | Compound | 63 | 0.10360504 |
| Trypsin-1 | Target | 63 | 0.02571407 |
| Cell division protein kinase 2 | Target | 62 | 0.00804666 |
| Glycogen synthase kinase-3 beta | Target | 61 | 0.0087541 |
| Peroxisome proliferator-activated receptor gamma | Target | 61 | 0.02602051 |
| Proto-oncogene serine/threonine-protein kinase Pim-1 | Target | 61 | 0.00731391 |
| Estrogen receptor beta | Target | 60 | 0.00760087 |
| Coagulation factor Xa | Target | 55 | 0.01878226 |
| Cyclin-A2 | Target | 53 | 0.00546001 |
| Nuclear receptor coactivator 2 | Target | 52 | 0.05181668 |
| Prostaglandin G/H synthase 1 | Target | 52 | 0.04921123 |
| Sodium channel protein type 5 subunit alpha | Target | 51 | 0.02323399 |
| Dipeptidyl peptidase IV | Target | 45 | 0.02031966 |
| 7-Methoxy-2-methyl isoflavone | Compound | 43 | 0.0274993 |
| Formononetin | Compound | 39 | 0.0438877 |
| beta-sitosterol | Compound | 38 | 0.06644929 |
| Thrombin | Target | 38 | 0.01452236 |
| Isorhamnetin | Compound | 37 | 0.03169965 |
| Naringenin | Compound | 37 | 0.1201062 |
| Medicarpin | Compound | 34 | 0.02391904 |
| mRNA of PKA Catalytic Subunit C-alpha | Target | 34 | 0.03269624 |
| licochalcone a | Compound | 32 | 0.02913105 |
| 2-[(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano[6,5-f]chromen-3-yl]-5-methoxyphenol | Compound | 31 | 0.00718614 |
| Beta-2 adrenergic receptor | Target | 31 | 0.01440293 |
| DNA topoisomerase II | Target | 31 | 0.00830063 |
| shinpterocarpin | Compound | 30 | 0.01309466 |
| Vestitol | Compound | 30 | 0.00877921 |
| Licoagrocarpin | Compound | 29 | 0.00658159 |
| Retinoic acid receptor RXR-alpha | Target | 28 | 0.01008831 |
| Glypallichalcone | Compound | 27 | 0.00712433 |
| Glyasperins M | Compound | 26 | 0.00616704 |
| Acetylcholinesterase | Target | 24 | 0.00976155 |
| Coagulation factor VII | Target | 22 | 0.00700284 |
| Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform | Target | 17 | 0.01365074 |
| Potassium voltage-gated channel subfamily H member 2 | Target | 16 | 0.00643202 |
| Nitric-oxide synthase, endothelial | Target | 14 | 0.00565094 |
| Demethoxycapillarisin | Compound | 13 | 0.01972483 |
Figure 2The PPI network of YCSND (the larger the node, the deeper the color, representing the greater the degree of the node).
Gene ontology term, cellular component, direct (Top 10).
|
|
|
| |
|---|---|---|---|
| extracellular space | 66 |
| 1.2×10−19 |
| Cytosol | 94 |
| 1.3×10−12 |
| plasma membrane | 103 |
| 1.3×10−10 |
| membrane raft | 19 |
| 6.0×10−10 |
| external side of plasma membrane | 18 |
| 7.2×10−9 |
| extracellular exosome | 75 |
| 1.3×10−8 |
| extracellular region | 52 |
| 1.5×10−8 |
| Caveola | 11 |
| 2.0×10−8 |
| endoplasmic reticulum membrane | 34 |
| 1.2×10−7 |
| endoplasmic reticulum | 33 |
| 1.5×10−7 |
Gene ontology term, molecular function, direct (Top 10).
|
|
|
| |
|---|---|---|---|
| enzyme binding | 49 |
| 1.4×10−33 |
| protein heterodimerization activity | 38 |
| 4.9×10−17 |
| drug binding | 18 |
| 8.2×10−16 |
| protein homodimerization activity | 45 |
| 1.6×10−15 |
| identical protein binding | 42 |
| 3.9×10−13 |
| RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding | 12 |
| 2.7×10−12 |
| transcription factor binding | 25 |
| 6.7×10−12 |
| protein kinase binding | 28 |
| 1.4×10−11 |
| protein binding | 183 |
| 2.0×10−11 |
| steroid hormone receptor activity | 13 |
| 2.8×10−11 |
Gene ontology term, biological process, direct (Top 10).
|
|
|
| |
|---|---|---|---|
| response to drug | 40 |
| 2.2×10−25 |
| positive regulation of transcription from RNA polymerase II promoter | 58 |
| 2.0×10−19 |
| response to ethanol | 22 |
| 3.6×10−18 |
| positive regulation of gene expression | 30 |
| 2.6×10−17 |
| aging | 24 |
| 3.8×10−16 |
| positive regulation of transcription, DNA-templated | 38 |
| 1.5×10−15 |
| xenobiotic glucuronidation | 9 |
| 1.9×10−14 |
| negative regulation of the fatty acid metabolic process | 9 |
| 1.9×10−14 |
| response to estradiol | 18 |
| 2.2×10−14 |
| positive regulation of nitric oxide biosynthetic process | 14 |
| 3.2×10−14 |
KEGG pathway enrichment (Top 10).
|
|
|
| |
|---|---|---|---|
| Pathways in cancer | 60 |
| 3.7×10−25 |
| Hepatitis B | 39 |
| 4.0×10−25 |
| Pancreatic cancer | 28 |
| 4.2×10−24 |
| Prostate cancer | 29 |
| 3.2×10−21 |
| TNF signaling pathway | 29 |
| 8.7×10−19 |
| Bladder cancer | 20 |
| 2.3×10−18 |
| Chagas disease (American trypanosomiasis) | 27 |
| 7.2×10−17 |
| Toxoplasmosis | 28 |
| 2.0×10−16 |
| Nonsmall cell lung cancer | 20 |
| 2.7×10−15 |
| Hepatitis C | 28 |
| 5.4×10−15 |